Confocal microscopy was done at the Microscopy, Imaging and Cytometry Resources Core at Wayne State University, School of Medicine

Confocal microscopy was done at the Microscopy, Imaging and Cytometry Resources Core at Wayne State University, School of Medicine. == Statistical analysis == Statistics were conducted using GraphPad Prism 5. 0 for Windows (GraphPad Software) and tests were done with a Studentttest (*P PTC124 (Ataluren) < 0. 05, **P < 0. 01, ***P < 0. 001). Pvalues less than 0. 05 were considered to be statistically significant. a mechanism of EHD3-mediated tumor suppression that involves the attenuation of endosomal signaling of the EGFR oncogene. Keywords: EHD3, EGFR, glioblastoma, signaling == INTRODUCTION == The National Cancer Institute (http://www.cancer.gov/cancertopics/types/brain) reports an estimated 22, 850 new cases and 15, 320 deaths from brain and other Central Nervous System (CNS) cancers in the US in 2015. Worldwide, in 2012, there were 256, 000 new cases diagnosed (http://www.wcrf.org/int/cancer-facts-figures/worldwide-data). Among primary intracranial tumors, gliomas are the most frequent. The World Health Organization (WHO) classification distinguishes between low (I and II) and high (III and IV) grade gliomas [1]. Grade IV astrocytomas, also known GP9 as glioblastomas or glioblastoma multiforme (GBM) constitute the highest and most prevalent grade [2]. GBM is a poorly differentiated astrocytic tumor, highly heterogeneous, extremely invasive and showing a complex biology [3]. GBM is characterized by an amplification and/or mutation of wild-type epidermal growth factor receptor (EGFR), amplification of the platelet-derived growth factor (PDGF) and receptors (PDGFR/), mutations of theIDH1andIDH2genes or loss of tumor suppressor genes such asp53, PTENorp16Ink4a. EGFRaberrations are the most widespread oncogenic events in GBMs, with a frequency of over 50% [4]. EGFR is known as a key Receptor Tyrosine Kinase (RTK) and a therapeutic target in many cancers including gliomas [57]. We have recently identifiedEhd3as a new putative glioma tumor suppressor, whose loss of expression is a very frequent event in gliomas PTC124 (Ataluren) of all grades [8]. The EHD3 protein belongs to the group of C-terminal Eps15 homology domain-containing (EHD) proteins, a relatively newly identified highly conserved family of proteins involved in endocytic trafficking. The EH domain is a motif of ~100 residues, typically found at the N-terminus of many proteins. However , in mammals, the EHD family of proteins has the EH domain at the C-terminus. This family of four paralogs (EHD1-EHD4) has been implicated in receptor intracellular trafficking, namely in internalization and recycling to the plasma membrane [9, 10]. In particular, although information is scarce, EHD3 was shown to be involved in early-endosome-to-recycling-endosome transport [11] and in the regulation of endosome-to-Golgi transport [12]. In this study, we sought to determine whether EHD3 regulates the trafficking, signaling and function of EGFR. It is well acknowledged that endocytosis and vesicular trafficking have an important role in regulation and integration of PTC124 (Ataluren) RTK signaling pathways and functions [1318]. Therefore , it is not surprising that these essential biological processes are involved in cancer progression [1921]. In particular, much effort is dedicated to identifying the mechanisms and proteins involved in EGFR trafficking in signal modulation, which remain largely unknown [17, 22]. Here we describe data showing that EHD3 regulates EGFR expression, activation, signaling and signal attenuation upon ligand stimulation. We show that by accelerating EGFR ubiquitination and sorting from the endosomes into a lysosomal degradation compartment, EHD3 has a specific inhibitory effect on Akt and ERK endosomal signaling, which could contribute to growth-inhibitory effects of high dose EGF ligand stimulation. == RESULTS == == EHD3 expression increases EGFR base levels in the absence of ligand stimulation == We have recently shown evidence that EHD3 PTC124 (Ataluren) possesses tumor suppressor functions in gliomas [8]. In light of the role of the EHD family of proteins in endocytic trafficking [9, 23], we hypothesized that at least parts of EHD3s functions might be mediated by regulating the trafficking of receptor tyrosine kinases (RTKs), and thus their signaling ability and functions. EGFR is known as a key RTK and leading therapeutic target in many PTC124 (Ataluren) cancers including gliomas [57]. We thus elected to assess whether EHD3 regulates the fate of EGFR. Using a Dox-inducible system, we examined the impact of restoring EHD3 expression to two glioma cell lines that express very low levels of EHD3, i. e. the U251 and U87MG cells, on the expression of EGFR. Contrary to our expectation, the expression of EHD3 in U251 cells resulted in higher levels of.